Avania Welcomes New Chief Executive

There’s a new leader in charge at Avania.

The company has appointed Jason Monteleone as president and CEO to succeed Sapna Hornyak, who had served in that role since 2019. Hornyak helped Avania develop a strong, integrated global medtech platform, which Monteleone will further enhance through growth initiatives, deeper therapeutic specialization, and innovation.

“I look forward to working closely with Jason as he leads Avania to continue making a positive impact for our customers, employees, and the medtech community. The executive team and board are excited about the future as we bring Avania to the forefront of innovation and operational excellence,” Avania Board Chairman Todd Pope said. 
 
With more than 25 years of experience in the clinical research organization (CRO), medical device, and life sciences sectors, Monteleone brings deep expertise in driving growth, innovation, and operational excellence. From 2017 until 2021, Monteleone was CEO of Clinipace, a global midsize CRO, where revenue increased 65% under his tenure before being acquired by dMed in April 2021. While chief financial officer at Theorem Clinical Research, a global midsize CRO focused on pharmaceutical and medical device studies, revenue and head count doubled before being acquired by Chiltern International in September 2015. Most recently, Monteleone was president of Ancillare, a global provider of ancillary supplies and equipment for clinical trials.

“We are excited to welcome Jason as Avania’s new CEO. His track record of driving growth and operational excellence, combined with his experience in scaling businesses, make him the perfect leader for Avania’s next phase,” Astorg Mid-Cap Partner/Co-Head Edouard Pillot stated. Astorg Mid-Cap is the majority shareholder in Avania. “With deep expertise in the CRO and medtech industries, Jason will drive innovation and deliver distinctive solutions for our customers. We look forward to seeing Avania create long-term value for its stakeholders under his leadership.”
 
Additionally, Monteleone is a board member and audit chair for the Drug Information Association (DIA), the leading global multidisciplinary life science membership association driving collaboration in drug, device, and diagnostic developmentd. He founded Pivotal Financial Consulting, advising investors and companies in clinical research on acquisitions, growth strategies, and innovation. Monteleone was also director of finance at VIASYS Healthcare, a publicly traded medical device company, before its acquisition by Cardinal Health and merger into CareFusion.
 
“I am honored to join Avania and lead this team at such an exciting time in our industry,” Monteleone commented. “Avania partners with some of the world’s most innovative companies in numerous therapeutic areas such as cardiovascular, neurology, orthopedics, and aesthetics to name a few. The privilege to assist our customers in developing life-changing products for patients is the reason we are passionate about what we do…”
 
Avania is a global full-service CRO focused on managing clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. Avania’s aims to be a global partner in the evolution of medical technology, from innovation to commercialization.